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Abstract
Treatment with prostaglandin(PG)-E2 is clinically efficient for cervical priming. The aim of this study
was to evaluate the impact of PG-E2 on the expression of the progesterone (PR), androgen (AR)
and glucocorticoid (GR) receptors in human uterine cervix in prolonged pregnancy.
The study groups were postterm nulliparous women with unripe cervices undergoing cervical
priming with PG-E2 before labor induction. Responders (n = 12) who delivered vaginally were
compared with non-responders (n = 10), who underwent cesarean section due to failure to
progress to the active phase of labor. Controls (n = 18) with vaginal partus at a normal gestational
age served as a reference group. Cervical levels of PR-A and PR- B isoforms, AR and GR, serum
levels of their ligands and sex hormone-binding globulin (SHBG) were quantified.
The responder group displayed lower total PR-AB and AR protein levels as compared to non-
responders, and lower PR-B and AR protein levels as compared to controls. In addition, the PR
mRNA level was lower in responders as compared to non-responders. The GR protein level did
not differ between the groups.
We conclude that successful PG-E2 priming was followed by a progesterone and androgen
withdrawal at the receptor level in the uterine cervix.
Background
In clinical practice, cases of maternal or fetal distress
necessitate immediate induction of labor. Prostaglandins
(PGs) from the E and F series are the main promoters of
cervical ripening and myometrial contractility. The influ-
ence of PG-E2 in promotion of cervical maturation and
uterine vasodilatation has been suggested as the primary
functions of PGs in human parturition [1]. Local treat-
ment with PG-E2 gel is efficient for cervical priming [1,2].
Prolonged pregnancy ≥ 42+0 gestational weeks occurs in
5-12% of pregnancies, predominantly in nulliparous
women, exerting increased risks for perinatal mortality
and morbidity [3-5]. Prolonged pregnancy is a key indica-
tion for cervical priming and induction of labor. The uter-
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ine cervix effaces towards the internal os and increases in
diameter during the latency phase of labor, and it opens
beyond 3-4 cm during the active phase. Late cervical rip-
ening resembles an inflammatory reaction [1,6,7]. Proges-
terone, testosterone and cortisol are known to have anti-
inflammatory properties [1,8,9].
Progesterone withdrawal associated with human parturi-
tion is characterized by decreased levels of the total pro-
gesterone receptor (PR) and an increased ratio of the
inhibitory PR-A isoform to PR-B isoform form in the uter-
ine cervix and myometrium [10-12].
The aim of this study was to evaluate the impact of PG-E2
priming on the expression of the PR, androgen (AR) and
glucocorticoid (GR) receptors in human uterine cervix in
prolonged pregnancy. Serum levels of the receptor lig-
ands, sex hormone-binding globulin (SHBG), and cervi-
cal expression of the prostaglandin synthase enzymes
constitutive cyclooxygenase (COX)-1 and inducible COX-
2 were also determined.
Methods
Study patients
Ethics committee approval was obtained before the study
(Karolinska University Hospital Ref No. 99-099). All
women were healthy, non-smoking, had uncomplicated
pregnancies, were without medication and gave informed
consent to participate in the study. The study groups were
nulliparous women with unripe cervices defined as a
Bishop score ≤ 5 points. A Bishop score of ≥ 6 points was
the criterion for a ripe cervix according to clinical guide-
lines [13]. The subjects were treated with PG-E2 in viscous
gel (Minprostin® Pharmacia, Sweden) for cervical priming
and labour induction in postterm pregnancy ≥ 42+0 ges-
tational weeks (Table 1, 2 and 3).
Nulliparous women (n = 18) with spontaneous onset of
labor and vaginal partus at a normal gestational length
served as a reference control (C) group. They had a
median age of 30 years (range 20-37) a median gesta-
tional age of 39+6 weeks (range 37+0-41+1). Oxytocin
infusion (Syntocinon® 10 U/glucose 2,5% 500 mL) for
augmentation of labor was administered to all women
according to the clinical guidelines [14].
The responders (R) were nulliparous women (n = 12)
who delivered vaginally after successful cervical priming
with PG-E2. They had a median age of 30 years (range 21-
39), a median gestational length of 42+4 weeks (range
42+1- 42+5) at partus, and median Bishop score of 3
points (range 0-4) at admission. All 12 women received
oxytocin infusion for augmentation of labor.
The non-responders (NR) were nulliparous women (n =
10) who failed to enter the active phase of labor after treat-
ment with PG-E2 and therefore delivered by cesarean sec-
tion [15]. They had a median age of 30 years (range 24-
37), a median gestational length of 42+4 weeks (range
42+1- 42+6) at partus, and a median Bishop score of 2
points (range 0-4) before PG-E2 treatment. Oxytocin infu-
sion was administered to 7 of 10 women for induction of
labor.
It was not possible to obtain a peripheral venous sample
from every subject, due to practical reasons or lack of con-
sent. The limited size of the cervical biopsies did not allow
for analysis of both mRNA and immunohistochemistry
(IHC) in all samples. Thus, the actual number for the
mRNA analyses is given in the Results section.
Sampling procedure
The cervical biopsies were obtained transvaginally from
the anterior part of the uterine cervix at the 12 o'clock
position, from 10-20 mm depth within 30 min after deliv-
ery. The biopsies were divided and one half was immer-
sion-fixed in 4% formaldehyde overnight, stored at 4°C
in 70% ethanol and thereafter embedded in paraffin. The
other half was immediately frozen at -70°C. Cervical tis-
sue obtained from women after partus at a normal gesta-
tional length served as reference material.
Serum analyses
Peripheral venous samples were drawn immediately after
parturition or at cesarean section. They were centrifuged at
3000 × G for 10 min and stored at -20 °C until analyzed.
Table 1: Clinical data controls.
Age Gest age Oxytocin Anaesthesia Weight Gender
27 37+5 + EDA 3190 M
37 39+6 + EDA 3965 M
30 39+4 + EDA 3280 M
34 40+3 + EDA 3625 M
21 37+0 + EDA 2595 F
29 40+3 + EDA 3665 F
20 40+5 + EDA 3815 F
23 40+6 + EDA 3065 M
30 39+3 + EDA 3130 M
32 41+1 + EDA 3420 M
32 40+5 + N2O 4175 M
28 39+5 + EDA 3470 M
31 40+1 + EDA 3590 F
26 40+4 + EDA 3390 F
31 40+1 + N2O 3540 M
27 39+3 + EDA 2970 M
26 41+0 + EDA 2815 F
36 38+6 + EDA 4055 M
37 40+5 + EDA 4130 F
30 39+6 19/19 17/19 3470 F7/M12
Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for 
augmentation of labor. EDA = epidural anaesthesia, N2O = inhalation 
of nitrous oxide 50%/oxygen 50%.Reproductive Biology and Endocrinology 2009, 7:116 http://www.rbej.com/content/7/1/116
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Serum levels of progesterone and SHBG were determined
by direct chemiluminiscence enzyme immunoassay using
commercially available kits from Diagnostic Products
Corp., Los Angeles, CA (Immulite®). Serum testosterone
was determined by direct radioimmunoassay using a kit
obtained from Diagnostic Products Corp. ("Coat-a-
Count®"). Serum 5α-DHT was determined after destruc-
tion of cross reacting testosterone by oxidative cleavage of
the 4-ene double bond with potassium permanganate fol-
lowed by extraction, using a kit from Diagnostic Systems
Laboratories Inc., Webster, Texas, U.S.A. Values obtained
by this method were compared with those obtained by a
method including extraction with diethyl ether, column
chromatography on celite and subsequent radioimmu-
noassay and an excellent correlation was found [16]. Cir-
culating progesterone binds in < 1%, testosterone in 70%,
and its active metabolite 5α-dehydrotestosterone (DHT)
in 28%, by high affinity to sex hormone-binding globulin
(SHBG) [17]. The free androgen index (FAI) (total T/
SHBG × 100) was calculated since the non SHBG-bound
fraction is the biologically active fraction of steroid hor-
mones [18].
RNA preparation and reverse transcription
Total RNA from frozen cervical tissue samples was puri-
fied with the RNeasy® kit (Qiagen GmbH, Hilden, Ger-
many) according to a procedure for RNA isolation from
fibrous tissues, including a DNase step, as recommended
by the manufacturer. Two μg of total RNA from each sam-
ple was reverse transcribed at 37°C for 60 min in a final
volume of 30 μl with a reaction mixture (Qiagen) contain-
ing 1 × RT buffer, dNTP mix (0.5 mM each dNTP), 600 ng
random primers (Invitrogen, Paisley, UK), 10 units RNase
inhibitor (Superase-In, Ambion, Austin, TX), and 4 U of
Omniscript™ reverse transcriptase (Qiagen).
Real time PCR analysis
The oligonucleotide primers for PR-AB, PR-B, AR and
Cyclophilin A are presented in Table 4, as well as their pre-
dicted sizes. Real time PCR was performed in a DNA
Table 2: Clinical data responders.
Age Gest age BS PG-E Oxytocin Anaesthesia Weight Gender
21 42+5 2 4 + EDA 3410 F
31 42+4 2 7 + EDA 4360 M
39 42+2 3 0,5 + EDA 2870 F
28 42+3 4 4 + EDA 3960 F
31 42+2 4 2 + EDA 3815 F
37 42+5 0 4 + EDA 3535 F
35 42+5 2 2 + EDA 4010 M
21 42+4 4 2 + N2O, EDA 3430 M
29 42+3 4 4 + N2O, EDA 3625 M
28 42+1 2 2 + EDA 4245 M
23 42+4 3 2 + EDA 3540 M
30 42+1 4 4 + EDA 3985 M
30 42+4 3 3,1 12/12 12/12 3732 F5/M7
BS = Bishop score (points) before priming, PG-E2 = accumulated PG-E2 dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for 
induction of labor. EDA = epidural anaesthesia, N2O = inhalation of nitrous oxide 50%/oxygen 50%.
Table 3: Clinical data non-responders.
Age Gest age BS PG-E Oxytocin Anaesthesia Weight Gender
32 42+4 2 6 - EDA 3730 F
24 42+3 2 2 + EDA 2830 F
31 42+3 2 5 + SPA 3565 F
29 42+6 0 5,5 - SPA 5130 M
26 42+5 0 4 - SPA 3960 F
33 42+4 2 6 + SPA 2905 M
29 42+4 2 6 + EDA 3630 F
28 42+5 3 6 + EDA 4180 M
37 42+4 3 1 + SPA 5060 M
32 42+6 2 6,5 + SPA 4930 M
30 42+4 2 4,7 7/10 10/10 3992 F5/M5
BS = Bishop score (points) before priming, PG-E2 = accumulated PG-E2 dose (mg), Oxytocin = infusion of oxytocin10 U/glucose 2,5% 500 mL for 
induction of labor. EDA = epidural anaesthesia, SPA = spinal anaesthesia, N2O = inhalation of nitrous oxide 50%/oxygen 50%.Reproductive Biology and Endocrinology 2009, 7:116 http://www.rbej.com/content/7/1/116
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Engine Opticon™ 2 System (MJ Research, Waltham, MA).
For PCR, the cDNAs corresponding to 40-100 ng (see
Table 2) RNA were added to 10 μl of Quantitect™ SYBR®
Green PCR mix (Qiagen) containing HotStarTaq DNA
polymerase, PCR buffer, dNTP mixture and 0.3 μM of
each oligonucleotide primer in a final volume of 20 μl.
The reactions were performed in opaque white 0.2 ml
low-profile strip tubes sealed with optical flat caps (TLS-
0851, TCS-0803, MJ Research). After initial incubation for
15 min at 95°C, the samples were subjected to 40-44
cycles of 10 s at 94°C, 15-20 s at 56°C (see Table 4) and
20 s at 72°C with a final extension step at 72°C for 5 min.
All PCR assays were performed twice. The purity of PCR
products was confirmed by a melting curve analysis in all
experiments (data not shown). All primers were designed
to span an intron/exon boundary or to flank an intron.
Thus, amplification of contaminating DNA was elimi-
nated. Each PCR assay included a negative control con-
taining a RNA sample without reverse transcription. The
primers were based on the sequences of the human genes.
The primer pairs (Table 4) were designed with Primer3
software [19].
Quantification of mRNA
To standardize the quantification method, cyclophilin A
was selected as the housekeeping gene. The PCR amplifi-
cation rate and the cycle threshold (Ct) values were ana-
lyzed using Opticon Monitor 3.0 software (MJ Research).
The values of relative expression of genes of interest were
normalized against the cyclophilin A product.
Immunohistochemical analysis
Immunostaining for the determination of PR-AB, PR-A,
PR-B, AR, GR, COX-1 and COX-2 utilizing the avidin-
biotin peroxidase complex (ABC) procedure was per-
formed [20]. The 5 μm paraffin sections prepared from
cervical biopsies were first dewaxed in Bioclear (Bio-
Optica, Milan, Italy), rehydrated and washed with phos-
phate-buffered saline (PBS; pH 7.4). Thereafter the sec-
tions were subjected to microwave antigen retrieval in
0.01 M sodium citrate buffer (pH 6.0) for 10 min and
then allowed to cool for 20 min. Subsequently, endog-
enous peroxidase activity was quenched by immersion in
3% hydrogen peroxide (Merck) in methanol for 10 min at
room temperature (RT); followed by blocking non-spe-
cific binding of the primary antibody by incubation as
shown in Table 5, at RT. The sections were then incubated
with the primary antibodies (see Table 5). For the negative
controls the primary antibody was replaced by mouse IgG
(or in the case of GR rabbit IgG, and for COX-1 and -2
goat IgG) at a corresponding concentration to the anti-
body it replaced.
The secondary biotinylated antibodies were incubated as
shown in Table 5, followed by incubation with an avidin-
biotin horseradish peroxidase complex (Vectastain Elite,
Cat# PK-6100) for 30 min at RT. The site of the bound
enzyme was visualized by the application of 3,3'-diami-
nobenzidine (DAB kit, Vector, CA), a chromogen which
produces a brown, insoluble precipitate when incubated
with enzyme. The sections were counterstained with hae-
matoxylin and dehydrated before they were mounted
with Pertex (Histolab, Gothenburg).
Image analysis
A Leica microscope and Sony video camera (Park Ridge,
NJ, U.S.A.) connected to a computer with an image anal-
ysis system (Leica Imaging System Ltd, Cambridge, UK)
was used to assess quantitative values from immunohisto-
chemistry. The quantification of immunostaining was
performed as described previously [20]. In short, by using
colour discrimination software the total area of positively
stained nuclei was measured, and expressed as a ratio of
the total area of cell nuclei.
Manual scoring
Two observers blinded to the identity of the slides per-
formed all the assessments. The staining was evaluated
Table 4: Oligonucleotide primers used for real-time PCR.
Gene Accession No Primers
F = forward; R = reverse
Position cDNA Annealing step
PRAB NM_000926.4
[37]
F: tggaagaaatgactgcatcg
R: agcatccagtgctctcacaa
bp 2555-2574
bp 2702-2683
product: 148 bp
40 ng 56°C/15 s
PRB NM_000926.4
[37]
F: gactgagctgaaggcaaagg
R: cgaaacttcaggcaaggtgtc
bp 746-765
bp 890-870
product: 145 bp
40 ng 56°C/15 s
AR NM_000044.2 F: taccagctcaccaagctcct
R: gcttcactgggtgtggaaat
bp 3687-3706
bp 3882-3861
product: 195 bp
100 ng 56°C/20 s
Cyclophilin A NM_021130.3 F: gtggtgtttggcaaagtgaa
R: tcgagttgtccacagtcagc
bp 462-481
bp 577-558
product: 116 bp
40 ng 56°C/20 sReproductive Biology and Endocrinology 2009, 7:116 http://www.rbej.com/content/7/1/116
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semi-quantitatively using a grading system. The staining
intensity was graded on a scale of (0) no staining, (1)
faint, (2) moderate or (3) strong staining.
Statistical analyses
Clinical data were calculated with ANOVA/ANCOVA and
significances were evaluated with Scheffe's test. Statistical
calculation for serum hormone levels, receptor and
mRNA levels was performed by ANOVA on ranks
(Kruskal-Wallis test) and significances were evaluated by
Dunn's test. Values with different letter designations are
significantly different at level p < 0.05.
Results
Clinical data
The median maternal age and fetal gender did not differ
between the groups. The neonatal weights were, as was
expected, significantly higher in the postterm NR and R
groups as compared to term C group (p < 0.05).
Serum levels of steroid hormones and SHBG
No differences were observed for progesterone, total testo-
sterone, 5α-DHT levels or FAI between C (n = 16), R (n =
8) and NR (n = 8) groups. Serum progesterone (medians
and range) was 299 (175-563) nmol/L in C, 220 (115-
394) in R, and 234 (159-423) in NR. Serum testosterone
was 3.06 (1.07-7.84) nmol/L in C, 3.42 (1.72-4.47) in R,
and 2.93 (2.13-7.81) in NR. Serum 5α-DHT was 1.02
(0.04-2.42) nmol/L in C, 0.96 (0.57-1.18) in R, and 0.77
(0.58-1.22) in NR. Serum SHBG was significantly lower
301 (248-424) nmol/L in NR (n = 7), as compared to C
512 (304-708) and R 504 (236-644), whereas the FAI (T/
SHBG × 100) was comparable between the groups 0.556
(0.187-2.56) in C, 0.770 (0.352-1.75) in R, and 0.834
(0.634-2.60) in NR.
mRNA levels
The PR-AB mRNA level was lower in responders as com-
pared to the non-responders. The ratio between PR-AB
and PR-B represents the PR-A mRNA level which did not
change between the groups (Figure 1, upper middle
panel). The PRB mRNA showed similar results as the PR-
AB mRNA, but differences between groups did not reach
significance. The AR mRNA level showed a tendency to be
increased in the NR group, but did not reach significance
(Figure 1, bottom panel).
Immunohistochemistry
The immunohistochemistry (IHC) scores for nuclear PR-
AB (top panel), PR-A (upper middle panel), PR-B (lower
middle panel) and AR (bottom panel) protein are pre-
sented in Figure 2 and representative images of the IHC
results are shown in Figure 3.
The IHC score for PR-AB was lower in responders as com-
pared to non-responders (Figure 2 top panel; Figure 3A-
C). The IHC score for PR-B was lower in responders as
compared to controls (Figure 2 lower middle panel; Fig-
ure 3G-I). The IHC score for PR-A did not differ between
study groups.
Table 5: Antibodies used in the study.
Protein Primary ab, 
company and 
order number
Type and 
dilution
Inc temp + time Blocking Biotinylated 2 nd 
Ab all diluted 
1:200
Buffer Inc time in RT
PRAB Zymed Lab Inc, 18-
0172
Mc mouse anti 
human 1:150
RT 60 min 1.5% NHS horse anti-mouse 1.5% NHS in PBS 45 min
PRA Novocastra Labs 
Ltd, NCL-PGR312
Mc mouse anti 
human 1:500
RT 60 min 1.5% NHS horse anti-mouse 1.5% NHS in PBS 45 min
PRB Affinity 
BioReagents Inc, 
MA1-411
Mc mouse Anti 
chick 1:100
RT 60 min 1.5% NHS horse anti-mouse 1.5% NHS in PBS 45 min
AR DakoCyto-mation 
Inc, M3562
Mc mouse anti 
human 1:100
+4°C o/n 2% NHS horse anti-mouse 2% NHS in PBS 30 min
GR Affinity Bio 
Reagents Inc, PA1-
511A
Pc rabbit anti 
human 1:1000
+4°C o/n 2% NGS goat anti rabbit 2% NGS in PBS 60 min
COX-1 Santa Cruz 
Biotechnology Inc, 
sc 1752
Pc goat anti human 
1:100
+37°C 60 min 10% NRS rabbit anti goat 10% NRS in PBS 30 min
COX-2 Santa Cruz 
Biotechnology Inc, 
sc 1745
Pc goat anti human 
1:100
+37°C 60 min 10% NRS rabbit anti goat 10% NRS in PBS 30 min
Mc = monoclonal, Pc = polyclonal
RT = room temperature
biotinylated horse anti-mouse (Vector, Cat# BA-2000)
biotinylated goat anti rabbit (Vector, Cat# BA-1000)
biotinylated rabbit anti goat (Vector, Cat# BA-5000)Reproductive Biology and Endocrinology 2009, 7:116 http://www.rbej.com/content/7/1/116
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Real-time PCR results for expression of PR-AB (upper), PR-AB/PR-B (upper middle), PR-B (lower middle) and AR (bottom)  mRNAs in human cervix from the C (n = 11), R (n = 10) and NR (n = 4) groups respectively Figure 1
Real-time PCR results for expression of PR-AB (upper), PR-AB/PR-B (upper middle), PR-B (lower middle) and 
AR (bottom) mRNAs in human cervix from the C (n = 11), R (n = 10) and NR (n = 4) groups respectively. The 
values of relative expression of target genes were normalized against cyclophilin A and displayed in arbitrary units. The ratio of 
PR-AB/PR-B represents the PR-A expression. The "box-and-whisker plot" represents the median value with 50% of all data fall-
ing within the box. The whiskers extend to the 5th and 95th percentiles. Boxes with different letter designations are signifi-
cantly different, p < 0.05.
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Immunohistochemical analysis revealed a significantly
lower AR expression in the responders as compared to
non-responders and controls (Figure 2 bottom panel; Fig-
ure 3J-L).
The IHC scores for stromal COX-1, COX-2 and GR did not
differ between groups (data not shown). Representative
images from immunostaining of COX-1 (M), COX-2 (N)
and GR (O) are shown in Figure 3 as well as a negative
control (P) where the primary antibody was replaced by
an equal amount of mouse IgG.
Discussion
Prolonged pregnancy constitutes a key indication for cer-
vical priming and induction of labor [3-5]. Local treat-
ment with PG-E2  gel has been shown to promote
degradation of the extracellular matrix by increasing
matrix metalloproteinase (MMP)-1 collagenase activity
and by altering the proteoglycan content [2,21,22]. Pros-
taglandin-E2 was reported to induce a functional proges-
terone withdrawal in vitro by increasing the inhibitory PR-
A over PR-B expression through the protein kinase (PK)-C
pathway in a human myometrial cell line (PHM1-31)
[23].
We found that serum levels of the receptor ligands were
unchanged between the groups. However, the responder
group displayed a lower cervical level of total PR-AB pro-
tein as compared to non-responders, and a lower cervical
PR-B isoform level as compared to controls. The PR
mRNA level was lower in responders as compared to non-
responders, whereas no difference was found for the
inhibitory PR-A isoform, which acts as a repressor of the
PR-B isoform and other steroid receptors such as AR and
GR [24]. Thus, decreased PR-AB and PR-B protein levels in
responders indicate that PG-E2 priming leading to vaginal
partus was associated with a nuclear PR withdrawal. The
decreased PR-AB level in responders as compared to non-
responders could be the consequence of a vaginal deliv-
ery. Nevertheless, the decreased PR-B level in responders
as compared to controls cannot be explained by a differ-
ent mode of delivery. Furthermore, PG-E2  promotes
chemotaxis in neutrophils and macrophages, which
enhances leukocyte extravasation into tissues by a syner-
gistic action with chemotactic interleukin (IL)-8
[1,25,26]. This is in accordance with the high leukocyte
density and immunostaining for IL-8 observed in
responders [27]. Pro-inflammatory cytokines activate the
key pro-inflammatory transcription factor nuclear factor
(NF)-κB, which was shown to exert a mutual negative
interaction with PR [8,28]. The comparable levels of COX-
2 between the groups could be explained by the oxytocin
treatment, since oxytocin initiates COX-2 gene transcrip-
tion [29]. In addition, mechanical stretch induces COX-2
activity [30].
Since the cervical AR protein level was lower in responders
not only as compared to non-responders who delivered
by cesarean sections, but also as compared to controls
who delivered spontaneously, the result cannot be
explained by a different mode of delivery. The low AR pro-
tein level in responders indicates that successful PG-E2
priming was followed by an androgen withdrawal at the
receptor level. This finding is in accordance with results
from in vitro studies, in which androgens were reported to
attenuate the synthesis of pro-inflammatory cytokines,
inhibit MMP-1 production and regulate cervical resistance
by altering the proteoglycan content [31-34]. Possible
responses to the androgen withdrawal reported here
could therefore be events leading to degradation of the
extracellular matrix and cervical maturation [21,22,32].
Comparing the results of mRNA and protein for PR-AB,
PR-A, PR-B and AR, all showed a similar expression pat-
tern, although only PR-AB displayed significant changes
for both mRNA and protein. The lack of significance for
mRNA levels of PR-B and AR could be due to the fact that
mRNA levels were detected in cervix tissue homogenate
whereas the protein levels were determined in stromal
nuclei.
The total GR protein level in human uterine cervical
stroma and squamous epithelium was decreased after
term labor as compared to late pregnancy [35], but no dif-
ferences were found between the groups in the present
study.
In conclusion, successful local PG-E2 treatment for cervi-
cal priming after prolonged pregnancy was correlated to a
progesterone and androgen withdrawal at the receptor
level. A comparable progesterone and androgen with-
drawal was neither observed in the non-responders, who
failed to enter the active phase of labor and underwent
cesarean sections, nor in the term control group with
spontaneous deliveries. The progesterone withdrawal is in
accordance with the previous study [36], whereas the pos-
sibility of an androgen withdrawal, to our knowledge, has
not been reported previously. We conclude that successful
PG-E2 priming was followed by a functional progesterone
and androgen withdrawal at the receptor level in the uter-
ine cervix. It is possible that treatment with an antiproges-
tin or an antiandrogen could serve as a supplement to PG-
E2 priming in non-responders.
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Immunostaining results for PR-AB (top), PR-A (upper middle), PR-B (lower middle) and AR (bottom) in stroma, as assessed by  image analysis in cervical samples from controls (C), responders (R) and non-responders (NR) Figure 2
Immunostaining results for PR-AB (top), PR-A (upper middle), PR-B (lower middle) and AR (bottom) in 
stroma, as assessed by image analysis in cervical samples from controls (C), responders (R) and non-respond-
ers (NR). The "box-and-whisker plot" represents the median value with 50% of all data falling within the box. The whiskers 
extend to the 5th and 95th percentiles. Boxes with different letter designations are significantly different, p < 0.05.
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Representative images of the immunostaining results for PR-AB (A-C), PR-A (D-F), PR-B (G-I), AR (J-L), COX-1 (M), COX-2  (N) and GR (O) Figure 3
Representative images of the immunostaining results for PR-AB (A-C), PR-A (D-F), PR-B (G-I), AR (J-L), 
COX-1 (M), COX-2 (N) and GR (O). A negative control is shown for monoclonal antibodies (P) where the primary anti-
body was replaced by an equal amount of mouse IgG. The magnification bars represent 30 μm in all images.
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